A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.
Also called NCT05394519
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT05394519 -
2021-005121-24 -
jRCT2031220671
-
- Other papers using this trial's data
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Austria, Canada, Germany, Hungary, India, Ireland, Japan, Malaysia, Poland, Puerto Rico, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05394519. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-01 (actual); primary completion 2025-01-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
- Acronym
- REDEFINE 2
- Condition
- Overweight
- Condition
- Obesity
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo cagrilintide
- Intervention (Drug)
- Placebo semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05394519- Content hash
5d6df9db480c35a59edf046ec2bb65f960bd57603b93e6fc485a171286715128